Session (CTI)

China’s healthcare system has undergone profound transformation in recent years, with Health Economics and Outcomes Research (HEOR) emerging as a critical discipline supporting evidence-based policy development and healthcare decision-making. Driven by national healthcare reforms and initiatives from the National Healthcare Security Administration (NHSA), the integration of health technology assessment (HTA) and real-world evidence (RWE) has accelerated the transition toward value-based healthcare, enabling more effective resource allocation, reimbursement decisions, and patient access to innovative therapies. This forum will bring together leading experts to discuss the latest advances in HEOR, healthcare reform, and evidence-informed decision-making in China. Through diverse perspectives and practical experiences, speakers will examine the development of healthcare policies, advances in innovative drug development, evolving reimbursement and pricing frameworks, and the expanding role of real-world evidence in shaping healthcare decisions. Moderated by Dr. Jing Wu, the session will provide an overview of China’s healthcare system, key achievements, and ongoing challenges. Dr. Yue Yang will discuss recent developments in drug approval pathways and emerging trends in innovative medicine development. Dr. Wen Chen will examine national reimbursement policies, drug price negotiations, and evolving evidence requirements for healthcare decision-making. Dr. Tao Guo will share real-world case studies highlighting how RWE is being applied to inform policy, optimize healthcare delivery, and improve patient outcomes. Together, the forum will provide valuable insights into China’s journey from policy evolution to practical implementation, highlighting lessons learned and opportunities for the future of evidence-based healthcare.